INOVIO PHARMACEUTICALS, INC. Operating Cash Flow
INOVIO PHARMACEUTICALS, INC. (INO) reported Operating Cash Flow of -$39.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$18.05M.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$21.59M.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$19.37M.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$21.57M.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$88.63M.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$104.08M.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$124.37M.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$216.22M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$18.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$39.64M 10-Q · filed 2026-08-12 | -$59.01M derived: sum of 3 quarters · filed 2026-08-12 | -$80.58M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$21.59M 10-Q · filed 2026-05-13 | -$40.96M derived: sum of 2 quarters · filed 2026-05-13 | -$62.54M derived: sum of 3 quarters · filed 2026-05-13 | -$83.35M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$19.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$40.94M derived: sum of 2 quarters · filed 2026-03-12 | -$61.76M derived: sum of 3 quarters · filed 2026-08-12 | -$88.63M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$21.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$42.38M derived: sum of 2 quarters · filed 2026-08-12 | -$69.26M 10-Q · filed 2025-11-10 | -$88.92M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$20.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$47.69M 10-Q · filed 2026-08-12 | -$67.35M derived: sum of 3 quarters · filed 2026-08-12 | -$94.79M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$26.87M 10-Q · filed 2026-05-13 | -$46.54M derived: sum of 2 quarters · filed 2026-05-13 | -$73.98M derived: sum of 3 quarters · filed 2026-05-13 | -$102.19M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$19.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$47.11M derived: sum of 2 quarters · filed 2026-03-12 | -$75.32M derived: sum of 3 quarters · filed 2026-03-12 | -$104.08M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$27.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$55.65M derived: sum of 2 quarters · filed 2025-11-10 | -$84.41M 10-Q · filed 2025-11-10 | -$110.69M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$28.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$56.97M 10-Q · filed 2025-08-12 | -$83.25M derived: sum of 3 quarters · filed 2025-08-12 | -$112.36M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$28.76M 10-Q · filed 2025-05-13 | -$55.04M derived: sum of 2 quarters · filed 2025-05-13 | -$84.15M derived: sum of 3 quarters · filed 2025-05-13 | -$116.46M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$26.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$55.39M derived: sum of 2 quarters · filed 2025-03-18 | -$87.70M derived: sum of 3 quarters · filed 2025-03-18 | -$124.37M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$29.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$61.43M derived: sum of 2 quarters · filed 2024-11-14 | -$98.09M 10-Q · filed 2024-11-14 | -$134.43M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$32.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$68.98M 10-Q · filed 2024-08-08 | -$105.32M derived: sum of 3 quarters · filed 2024-08-08 | -$172.78M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$36.66M 10-Q · filed 2024-05-13 | -$73.00M derived: sum of 2 quarters · filed 2024-05-13 | -$140.47M derived: sum of 3 quarters · filed 2024-05-13 | -$191.00M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$36.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$103.81M derived: sum of 2 quarters · filed 2024-03-06 | -$154.33M derived: sum of 3 quarters · filed 2024-03-06 | -$216.22M 10-K · filed 2024-03-06 |
| 2022-09-30 | -$67.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$117.99M derived: sum of 2 quarters · filed 2023-11-09 | -$179.88M 10-Q · filed 2023-11-09 | -$217.77M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | -$50.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$112.41M 10-Q · filed 2023-08-09 | -$150.30M derived: sum of 3 quarters · filed 2024-03-06 | -$196.79M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | -$61.88M 10-Q · filed 2023-05-10 | -$99.77M derived: sum of 2 quarters · filed 2024-03-06 | -$146.26M derived: sum of 3 quarters · filed 2024-03-06 | -$224.72M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | -$37.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$84.38M derived: sum of 2 quarters · filed 2024-03-06 | -$162.84M derived: sum of 3 quarters · filed 2024-03-06 | -$215.71M 10-K · filed 2024-03-06 |
| 2021-09-30 | -$46.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$124.95M derived: sum of 2 quarters · filed 2022-11-08 | -$177.82M 10-Q · filed 2022-11-08 | -$229.03M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$78.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$131.33M 10-Q · filed 2022-08-09 | -$182.54M derived: sum of 3 quarters · filed 2023-03-01 | -$256.70M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$52.87M 10-Q · filed 2022-05-10 | -$104.08M derived: sum of 2 quarters · filed 2023-03-01 | -$178.24M derived: sum of 3 quarters · filed 2023-03-01 | -$205.39M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$51.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$125.37M derived: sum of 2 quarters · filed 2023-03-01 | -$152.53M derived: sum of 3 quarters · filed 2023-03-01 | -$177.98M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$74.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$101.31M derived: sum of 2 quarters · filed 2021-11-09 | -$126.76M 10-Q · filed 2021-11-09 | -$140.50M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$27.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$52.60M 10-Q · filed 2021-08-09 | -$66.34M derived: sum of 3 quarters · filed 2022-03-01 | -$94.08M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$25.45M 10-Q · filed 2021-05-10 | -$39.19M derived: sum of 2 quarters · filed 2022-03-01 | -$66.92M derived: sum of 3 quarters · filed 2022-03-01 | -$90.85M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$13.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$41.47M derived: sum of 2 quarters · filed 2022-03-01 | -$65.40M derived: sum of 3 quarters · filed 2022-03-01 | -$97.85M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$27.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$51.66M derived: sum of 2 quarters · filed 2020-11-09 | -$84.11M 10-Q · filed 2020-11-09 | -$101.39M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$23.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$56.38M 10-Q · filed 2020-08-10 | -$73.66M derived: sum of 3 quarters · filed 2021-03-01 | -$98.33M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$32.45M 10-Q · filed 2020-05-11 | -$49.74M derived: sum of 2 quarters · filed 2021-03-01 | -$74.41M derived: sum of 3 quarters · filed 2021-03-01 | -$93.43M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$17.28M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$41.95M derived: sum of 2 quarters · filed 2021-03-01 | -$60.97M derived: sum of 3 quarters · filed 2021-03-01 | -$73.55M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$24.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$43.69M derived: sum of 2 quarters · filed 2019-11-12 | -$56.27M 10-Q · filed 2019-11-12 | -$70.22M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | -$19.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$31.60M 10-Q · filed 2019-08-08 | -$45.55M derived: sum of 3 quarters · filed 2020-03-12 | -$62.86M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | -$12.58M 10-Q · filed 2019-05-09 | -$26.52M derived: sum of 2 quarters · filed 2020-03-12 | -$43.84M derived: sum of 3 quarters · filed 2020-03-12 | -$60.56M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | -$13.95M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$31.26M derived: sum of 2 quarters · filed 2020-03-12 | -$47.98M derived: sum of 3 quarters · filed 2020-03-12 | -$63.21M 10-K · filed 2020-03-12 |
| 2017-09-30 | -$17.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$34.03M derived: sum of 2 quarters · filed 2018-11-08 | -$49.26M 10-Q · filed 2018-11-08 | -$64.16M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | -$16.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$31.95M 10-Q · filed 2018-08-07 | -$46.85M derived: sum of 3 quarters · filed 2019-03-12 | -$65.49M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | -$15.23M 10-Q · filed 2018-05-09 | -$30.13M derived: sum of 2 quarters · filed 2019-03-12 | -$48.77M derived: sum of 3 quarters · filed 2019-03-12 | -$62.04M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | -$14.90M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$33.55M derived: sum of 2 quarters · filed 2019-03-12 | -$46.82M derived: sum of 3 quarters · filed 2019-03-12 | -$62.56M 10-K · filed 2019-03-12 |
| 2016-09-30 | -$18.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$31.91M derived: sum of 2 quarters · filed 2017-11-08 | -$47.65M 10-Q · filed 2017-11-08 | -$54.43M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | -$13.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$29.01M 10-Q · filed 2017-08-08 | -$35.78M derived: sum of 3 quarters · filed 2018-03-14 | -$20.36M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | -$15.74M 10-Q · filed 2017-05-10 | -$22.51M derived: sum of 2 quarters · filed 2018-03-14 | -$7.09M derived: sum of 3 quarters · filed 2018-03-14 | -$16.11M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | -$6.77M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $8.65M derived: sum of 2 quarters · filed 2018-03-14 | -$370.53K derived: sum of 3 quarters · filed 2018-03-14 | -$12.44M 10-K · filed 2018-03-14 |
| 2015-09-30 | $15.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $6.40M derived: sum of 2 quarters · filed 2016-11-09 | -$5.66M 10-Q · filed 2016-11-09 | -$13.74M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | -$9.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$21.09M 10-Q · filed 2016-08-08 | -$29.16M derived: sum of 3 quarters · filed 2017-03-15 | -$37.21M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | -$12.07M 10-Q · filed 2016-05-09 | -$20.14M derived: sum of 2 quarters · filed 2017-03-15 | -$28.19M derived: sum of 3 quarters · filed 2017-03-15 | -$36.33M derived: sum of 4 quarters · filed 2017-03-15 |
| 2014-12-31 | -$8.07M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$16.12M derived: sum of 2 quarters · filed 2017-03-15 | -$24.27M derived: sum of 3 quarters · filed 2017-03-15 | -$29.82M 10-K · filed 2017-03-15 |
| 2014-09-30 | -$8.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$16.19M derived: sum of 2 quarters · filed 2015-11-09 | -$21.75M 10-Q · filed 2015-11-09 | -$20.87M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | -$8.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$13.71M 10-Q · filed 2015-08-10 | -$12.83M derived: sum of 3 quarters · filed 2016-03-14 | -$18.54M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-03-31 | -$5.56M 10-Q · filed 2015-05-11 | -$4.68M derived: sum of 2 quarters · filed 2016-03-14 | -$10.39M derived: sum of 3 quarters · filed 2016-03-14 | -$15.81M derived: sum of 4 quarters · filed 2016-03-14 |
| 2013-12-31 | $874.90K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$4.83M derived: sum of 2 quarters · filed 2016-03-14 | -$10.25M derived: sum of 3 quarters · filed 2016-03-14 | -$15.38M 10-K · filed 2016-03-14 |
| 2013-09-30 | -$5.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$11.13M derived: sum of 2 quarters · filed 2014-11-10 | -$16.26M 10-Q · filed 2014-11-10 | -$21.78M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-06-30 | -$5.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$10.55M 10-Q · filed 2014-08-11 | -$16.07M derived: sum of 3 quarters · filed 2015-03-16 | -$22.11M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-03-31 | -$5.13M 10-Q · filed 2014-05-12 | -$10.65M derived: sum of 2 quarters · filed 2015-03-16 | -$16.69M derived: sum of 3 quarters · filed 2015-03-16 | -$22.00M derived: sum of 4 quarters · filed 2015-03-16 |
| 2012-12-31 | -$5.52M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | -$11.56M derived: sum of 2 quarters · filed 2015-03-16 | -$16.87M derived: sum of 3 quarters · filed 2015-03-16 | -$22.31M 10-K · filed 2015-03-16 |
| 2012-09-30 | -$6.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | -$11.35M derived: sum of 2 quarters · filed 2013-11-12 | -$16.78M 10-Q · filed 2013-11-12 | -$21.32M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-06-30 | -$5.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$10.75M 10-Q · filed 2013-08-09 | -$15.29M derived: sum of 3 quarters · filed 2014-03-17 | -$20.55M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-03-31 | -$5.44M 10-Q · filed 2013-05-10 | -$9.97M derived: sum of 2 quarters · filed 2014-03-17 | -$15.24M derived: sum of 3 quarters · filed 2014-03-17 | -$19.69M derived: sum of 4 quarters · filed 2014-03-17 |
| 2011-12-31 | -$4.53M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | -$9.80M derived: sum of 2 quarters · filed 2014-03-17 | -$14.25M derived: sum of 3 quarters · filed 2014-03-17 | -$19.76M 10-K · filed 2014-03-17 |
| 2011-09-30 | -$5.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | -$9.72M derived: sum of 2 quarters · filed 2012-11-07 | -$15.22M 10-Q · filed 2012-11-07 | -$18.57M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-06-30 | -$4.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | -$9.96M 10-Q · filed 2012-08-09 | -$13.30M derived: sum of 3 quarters · filed 2013-03-18 | -$14.09M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-03-31 | -$5.50M 10-Q · filed 2012-05-09 | -$8.85M derived: sum of 2 quarters · filed 2013-03-18 | -$9.63M derived: sum of 3 quarters · filed 2013-03-18 | |
| 2010-12-31 | -$3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | -$4.13M derived: sum of 2 quarters · filed 2013-03-18 | -$11.94M 10-K · filed 2013-03-18 | |
| 2010-09-30 | -$783.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | -$8.59M 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | -$7.81M 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | -$14.08M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |